Table 3.
Hepcidin antagonists validated in vivo.
| Drug | Target | Reference |
|---|---|---|
| Tocilizumab (monoclonal IL-6 receptor Ab) | IL-6 receptor | Song et al., 2010 |
| Siltuximab (monoclonal IL-6 Ab) | IL-6 | Casper et al., 2015 |
| Curcumin | STAT3 | Jiao et al., 2009 |
| AG490 (small molecule) | JAK2 | Zhang et al., 2011 |
| Heparin | BMPs | Poli et al., 2011 |
| glycol-split heparins | BMPs | Poli et al., 2014a |
| highly sulfated heparins | BMPs | Poli et al., 2014b |
| monoclonal HJV Ab | HJV | Abbvie (www.abbvie.com) |
| sHJV.Fc | BMPs | Theurl et al., 2011 |
| Dorsomorphin (small molecule) | type I BMPRs | Yu et al., 2008 |
| LDN-193189 (small molecule) | type I BMPRs | Steinbicker et al., 2011 |
| TP-0184 (small molecule) | ALK2 | Tolero Pharmaceuticals (www.toleropharma.com) |
| 1,25-dihydroxy-vitamin D | Vitamin D receptor | Bacchetta et al., 2014 |
| 17β–estradiol | estrogen-responsive promoter | Yang et al., 2012 |
| Testosterone | EGFR | Latour et al., 2014 |
| LY2787106 (monoclonal hepcidin Ab) | Hepcidin | Eli Lily and Company (www.lilly.com) |
| PRS-808 (PEGylated anticalin) | Hepcidin | Pieris Pharmaceuticals Inc (www.pieris.com) |
| NOX-H94 (PEGylated Spiegelmer) | Hepcidin | Schwoebel et al., 2013 NOXXON Pharma AG (www.noxxon.com) |
| LY2928057 (monoclonal FPN Ab) | FPN | Witcher et al., 2013 Eli Lily and Company (www.lilly.com) |